CASE STUDY

European Asset Due Diligence

Bringing European markets’ price, access and reimbursement insight to support global in-licensing decisions

Situation

A major global pharma company was considering therapy area expansion through in-licensing

The global Business Development team recognised the need for European HTA, price & reimbursement insights but the in-house European market access team lacked bandwidth to respond quickly

Action

AESARA deployed a team of industry-veteran strategy consultants and payer researchers to:

  • Execute a 4-week project, combining secondary and primary research with experience-based AESARA analysis,

  • Quickly and succinctly assess the European value & access opportunity for the asset

  • Test product value and price assumptions via double-blind interviews with European HCPs and payers/HTA advisors

  • Identify the BD&L implications for client decision-makers

Enabling Activity

Training development & delivery

Region

Europe

Client

Global Head of HEOR

IMPACT

A timely, clear and well-presented report covering,
for priority European markets:

  • Market size/opportunity
  • HTA insights
  • TPP value
  • Price potential

Enabled executive decision on go/no-go for the opportunity

Fit your need? Let us help.

EUROPE OFFICE